On September 30, 2020, the Third Circuit reversed a decision by the Eastern District of Pennsylvania ordering AbbieVie, Inc. (“AbbieVie”) and Besins Healthcare Inc. (“Besins”) to pay $448 million in disgorgement of ill-gotten profits for allegedly filing sham patent lawsuits to stifle competition. AbbieVie and Besins had filed patent infringement lawsuits against two developers of generic alternatives to its brand-name testosterone gel product AndroGel. The FTC sued AbbieVie and Besins in 2014 alleging that the patent suits were baseless and brought for no other ...
Blog Editors
Recent Updates
- A Potential New Path for School Districts to Settle Child Victims Act Cases: New York’s Limited Finance Law Amended to Assist School Districts
- State Cannot Immunize Parties from Federal Civil Liability - SCOTUS Today
- Good Faith, Bad Timing: Musk, Privilege, and the Price of the Advice-of-Counsel Defense
- Term Begins with Easy Unanimity, a Condition Soon to Be Forgotten - SCOTUS Today
- Service and Justice: Veterans in Law – Speaking of Litigation Video Podcast